Roche Drug Shows Improved Progression-Free Survival in Phase III Study
Roche Holding AG announced that its giredrestrant combination therapy demonstrated improved progression-free survival in a Phase III study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.